Clinical Trials on Bone Marrow in Japan

Total 434 results

Pfizer

Active, not recruiting

ATGAM General Investigation

Aplastic Anemia

Japan
Kyowa Kirin Co., Ltd.

Completed

Study of AMG531(Romiplostim) in Patients With Aplastic Anemia

Aplastic Anemia

Japan
Kyowa Kirin Co., Ltd.

Completed

Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia

Aplastic Anemia

Japan
Kyowa Kirin Co., Ltd.

Enrolling by invitation

Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia

Aplastic Anemia

Japan
Nagoya University

Unknown

Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAA

Acquired Aplastic Anemia.

Japan
Kyowa Kirin Co., Ltd.

Completed

Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia

Aplastic Anemia

Japan, Korea, Republic of
Pfizer

Completed

A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia

Aplastic Anemia

Japan
Perseus Proteomics Inc.

Recruiting

Safety Evaluation Study for Patients With Polycythemia Vera

Polycythemia Vera

Japan
Novartis Pharmaceuticals

Completed

Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects

Aplastic Anemia

Japan
PharmaEssentia Japan K.K.

Recruiting

A Study to Evaluate P1101 in Japanese PV Patients

Polycythemia Vera (PV)

Japan
Novartis Pharmaceuticals

Completed

A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia

Cytopaenia

Japan
Novartis Pharmaceuticals

Active, not recruiting

Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia (REACTS)

Severe Aplastic Anemia (SAA)

Japan, Korea, Republic of, China, Taiwan
PharmaEssentia Japan K.K.

Recruiting

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Polycythemia Vera (PV)

Japan
PharmaEssentia Japan K.K.

Completed

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

Polycythemia Vera (PV)

Japan
Otsuka Pharmaceutical Co., Ltd.

Active, not recruiting

Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes

Lower-risk Myelodysplastic

Japan
Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

Japan
Boehringer Ingelheim

Terminated

Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

Japan
Kyowa Kirin Co., Ltd.

Completed

A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome

MDS

Japan, Korea, Republic of
SymBio Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
Celgene

Completed

A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

Japan
Bristol-Myers Squibb

Active, not recruiting

Real-World Practice Patterns and Outcomes of Lower-Risk Myelodysplastic Syndrome Patients in Japan

Lower-risk Myelodysplastic Syndromes

Japan
Sanofi

Completed

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Myelofibrosis

Japan
Astellas Pharma Inc

Completed

A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients

Bone Marrow Transplantation | Graft Versus Host Disease | Graft-Versus-Host Disease | Graft-Vs-Host Disease

Japan
Kanto CML Study Group
Epidemiological and Clinical Research Information Network

Completed

A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib (CMR-CML)

Chronic Myeloid Leukemia

Japan
Kanto CML Study Group
Epidemiological and Clinical Research Information Network

Completed

A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

Japan
Astellas Pharma Inc

Completed

A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-

Bone Marrow Transplantation | Graft Versus Host Disease | Graft-Versus-Host Disease | Graft-Vs-Host Disease

Japan
SymBio Pharmaceuticals

Completed

Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
Kanto CML Study Group

Unknown

Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan (D-First)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Myelogenous Leukemia, Chronic, Chronic Phase

Japan
SymBio Pharmaceuticals

Withdrawn

Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
Celgene

Completed

A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Japan
Kanto CML Study Group

Unknown

Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial

Myelogenous Leukemia, Chronic, Chronic Phase

Japan
Shimousa Hematology Study Group
Epidemiological and Clinical Research Information Network

Unknown

Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

Chronic Myeloid Leukemia

Japan
Pfizer

Completed

Safety And Efficacy Of Bosutinib (BLF)

Chronic Myelogenous Leukemia

Japan
Incyte Corporation
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Polycythemia Vera

United States, Canada, France, Italy, United Kingdom, China, Belgium, Germany, Spain, Turkey, Japan, Australia, Korea, Republic of, Netherlands, Russian Federation, Argentina, Thailand, Hungary
OncoVerity, Inc.
Janssen Pharmaceutical K.K.; argenx

Completed

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

Leukemia, Myeloid, Acute

Japan
Celgene

Active, not recruiting

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Primary Myelofibrosis

Japan
SymBio Pharmaceuticals

Completed

Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Myelodysplastic Syndrome

Japan
Astellas Pharma Inc
Ono Pharma USA Inc

Completed

A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation

Bone Diseases | Osteoporosis | Osteoporosis, Postmenopausal

Japan
Takeda

Completed

36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate 75 mg Tablets

Osteoporosis

Japan
Celgene

Completed

Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.

Myelodysplastic Syndromes

Japan
SymBio Pharmaceuticals

Completed

Study of SyB C-1101 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
Novartis Pharmaceuticals

Completed

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia

Japan
Incyte Corporation

Recruiting

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (LIMBER)

Myeloproliferative Neoplasms

Spain, Japan, France, Italy, Germany, Australia, United Kingdom, Denmark, Canada
Eli Lilly and Company

Completed

A Study of Teriparatide in Japanese Osteoporosis Patients

Osteoporosis

Japan
Millennium Pharmaceuticals, Inc.

Completed

A Study of Pevonedistat in Adult East Asian Participants

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Japan, Taiwan, Korea, Republic of
Tokyo Medical University

Recruiting

Image Fusion System for 3D Preoperative Planning in the Osteosynthesis and Osteotomy

Fractures, Bone | Fracture Malunion, Bone

Japan
Pfizer

Terminated

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

United States, Japan
Shinshu University

Recruiting

The Effectiveness of Eldecalcitol in the Bisphosphonate Non-respondered-patients With Osteoporosis

Osteoporosis

Japan

3

Subscribe